Skip to Content
Merck
CN

T4580

Tiludronate disodium salt hydrate

≥98% (HPLC)

Synonym(s):

Skelid, Tiludronic acid disodium, [[(4-Chlorophenyl)thio]methylene]bisphosphonic acid disodium salt hydrate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C7H7ClNa2O6P2S · xH2O
CAS Number:
89987-06-4
Molecular Weight:
362.57 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
329826798
UNSPSC Code:
12352200
MDL number:
MFCD16872037

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Tiludronate disodium salt hydrate, ≥98% (HPLC)

InChI key

SZVJRJRMQCKFON-UHFFFAOYSA-L

SMILES string

O.[Na+].[Na+].OP([O-])(=O)C(Sc1ccc(Cl)cc1)P(O)([O-])=O

InChI

1S/C7H9ClO6P2S.2Na.H2O/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14;;;/h1-4,7H,(H2,9,10,11)(H2,12,13,14);;;1H2/q;2*+1;/p-2

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to off-white

solubility

H2O: >10 mg/mL, clear

originator

Sanofi Aventis

Quality Level

100

Related Categories

Biochem/physiol Actions

Tiludronate is a bisphosphonate bone resorption inhibitor. Tiludronate inhibits protein-tyrosine-phosphatase, leading to detachment of osteoclasts from the bone surface. It also inhibits the osteoclastic proton pump and is used to treat Paget′s disease.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Tiludronate disodium salt hydrate is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000222909
0000222907
0000222909
0000222907
040M4737V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Virginie Coudry et al.
American journal of veterinary research, 68(3), 329-337 (2007-03-03)
To evaluate the efficacy of tiludronate for the treatment of horses with signs of pain associated with lesions of the thoracolumbar vertebral column. 29 horses with clinical manifestations of pain associated with lesions of the thoracolumbar vertebral column and abnormal
Katja F Duesterdieck-Zellmer et al.
American journal of veterinary research, 73(10), 1530-1539 (2012-09-28)
To determine concentration-dependent effects of tiludronate on cartilage explants incubated with or without recombinant equine interleukin-1β (rEq IL-1). Articular cartilage explants from the femorotibial joints of 3 young adult horses. Cartilage explants were incubated with 1 of 6 concentrations (0
Peter Alexandersen et al.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 20(4), 588-595 (2005-03-15)
A new resorption assay measuring non-isomerized collagen type I C-telopeptide fragments (alpha-alpha CTX) was evaluated in a cohort comprising 32 Pagetic patients and 48 healthy controls. alpha-alpha CTX was found to be a sensitive marker for assessing disease activity and
Patricia Pascaud et al.
Langmuir : the ACS journal of surfaces and colloids, 29(7), 2224-2232 (2013-01-16)
Bisphosphonates (BPs) are well established as successful antiresorptive agents for the prevention and treatment of bone diseases such as osteoporosis and Paget's disease. The aim of this work was to clarify the reaction mechanisms between a BP molecule, tiludronate, and
Jean-Pierre Pelletier et al.
The Journal of rheumatology, 38(1), 118-128 (2010-10-19)
to investigate over a 1-year period in dogs that underwent extracapsular stabilization surgery (ECS) following anterior cruciate ligament (ACL) transection: whether reconstructive surgery could prevent osteoarthritis (OA) progression and whether treatment with the bisphosphonate tiludronic acid (TA) could improve the
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service